PHIO (Phio Pharmaceuticals) Asil keuangan resik

Patent conflicts and tissue regeneration challenges are hindering Phio Pharmaceuticals (PHIO) from reaching profitability. The company's operating profit, as visualized by the GURU.Markets platform, confirms this, stabilizing at -0.01. Future growth relies on the commercialization of the INTASYL system for dermatology, while scaling potential is based on joint research into new immuno-oncology combinations with partners.

This indicator tracks daily net income, allowing for an objective assessment of the business's fundamental stability and the allocation of risks across assets. By analyzing the current profit levels of Phio Pharmaceuticals (PHIO), investors can compare revenue trends against the company's expenditures on early-stage RNA drug development and the minimal costs associated with complying with basic environmental standards for biomaterial disposal.